67 related articles for article (PubMed ID: 38566092)
1. Oncolytic Tanapoxvirus Recombinants Expressing Flagellin C or Mouse Interleukin-2 Are Capable of Regressing Human Triple-Negative Breast Cancer Xenografts in Immuno-Competent BALB/c Nude Mice.
Monaco ML; Filpi GA; Kohler SL; Eversole R; Idris OA; Essani K
Pathogens; 2024 May; 13(5):. PubMed ID: 38787254
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice.
Dong J; Kong L; Wang S; Xia M; Zhang Y; Wu J; Yang F; Zuo S; Wei J
J Exp Clin Cancer Res; 2024 Apr; 43(1):102. PubMed ID: 38566092
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.
Zhu W; Zhang H; Shi Y; Song M; Zhu B; Wei L
Cancer Biol Ther; 2013 Nov; 14(11):1016-23. PubMed ID: 24025362
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models.
Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Oncotarget; 2016 Dec; 7(51):85273-85282. PubMed ID: 27863373
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
Ang L; Guo L; Wang J; Huang J; Lou X; Zhao M
Cancer Lett; 2020 Jun; 479():42-53. PubMed ID: 32200038
[TBL] [Abstract][Full Text] [Related]
6. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
7. Disrupting cholesterol esterification by bitter melon suppresses triple-negative breast cancer cell growth.
Shim SH; Sur S; Steele R; Albert CJ; Huang C; Ford DA; Ray RB
Mol Carcinog; 2018 Nov; 57(11):1599-1607. PubMed ID: 30074275
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma.
Wang S; Yan W; Kong L; Zuo S; Wu J; Zhu C; Huang H; He B; Dong J; Wei J
Nat Commun; 2023 Jul; 14(1):4367. PubMed ID: 37474548
[TBL] [Abstract][Full Text] [Related]
9. Correlations between serum lipid and Ki-67 levels in different breast cancer molecular subcategories.
Sun XB; Liu WW; Wang B; Yang ZP; Tang HZ; Lu S; Wang YY; Qu JX; Rao BQ
Oncol Lett; 2023 Feb; 25(2):53. PubMed ID: 36644143
[TBL] [Abstract][Full Text] [Related]
10. Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.
Ono R; Nishimae F; Wakida T; Sakurai F; Mizuguchi H
Sci Rep; 2022 Dec; 12(1):21560. PubMed ID: 36513733
[TBL] [Abstract][Full Text] [Related]
11. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms for ABCA1-mediated cholesterol efflux.
Chen L; Zhao ZW; Zeng PH; Zhou YJ; Yin WJ
Cell Cycle; 2022 Jun; 21(11):1121-1139. PubMed ID: 35192423
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein A1-Related Proteins and Reverse Cholesterol Transport in Antiatherosclerosis Therapy: Recent Progress and Future Perspectives.
Xu X; Song Z; Mao B; Xu G
Cardiovasc Ther; 2022; 2022():4610834. PubMed ID: 35087605
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
